Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 Nov;67(6):396–405. doi: 10.1016/j.curtheres.2006.12.004

In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity

L Yohani Pérez 1,*, Roberto Menéndez 1, Rosa Má 1, Rosa M González 1
PMCID: PMC3965969  PMID: 24678112

Abstract

Background:

D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia), has been found to reduce prostatic hyperplasia (PH) induced with testosterone (T), but not PH induced with dihydrotestosterone (DHT), in rodents, suggesting the inhibition of prostate 5α-reductase activity.

Objectives:

The aims of this study were to assess whether D-004 inhibits prostate 5α-reductase activity in vitro and to examine the effects of D-004 on enzyme kinetics.

Methods:

This experimental study was conducted at the Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana, Cuba. Soluble rat prostate preparations were used as the source of 5α-reductase, and (3H)-DHT production was measured to determine prostate 5α-reductase activity. Cell-free rat prostate homogenates were pre-incubated with carboxymethyl cellulose 2% alone (control tubes) or D-004 (0.24–125 μg/mL) suspended in the vehicle (treated tubes) for 10 minutes prior to adding the labeled substrate (3H)-T Once the reaction was stopped, sterols were extracted with chloroform and aliquots were applied on silica gel plates developed in benzene-acetone (4:1, v/v). Areas containing DHT were scraped and radioactivity was counted. The median inhibitory concentration (IC50) was determined by measuring the conversion of T to DHT The apparent Michaelis-Menten constant (Km) and Vmax values before and after adding D-004 were determined in kinetic studies using labeled T (0.5-25 μmol/L).

Results:

Compared with controls, D-004 significantly and dose-dependently inhibited the enzymatic reaction at doses of 1.95 to 125.0 μg/mL) (all, P < 0.05). The IC50 of D-004 required to inhibit 5a-reductase activity was 2.25 μg/mL. Enzyme inhibition was noncompetitive, since D-004 lowered the Vmax from 15.3 to 10.0 nmol DHT/min · mg−1 protein, while the Km (4.54 μmol/L) was almost unaffected.

Conclusions:

D-004 dose-dependently and noncompetitively inhibited in vitro 5α-reductase activity in soluble fractions of rat prostate. Although the extent of the maximal inhibition was high and the value of IC50 was low, the relevance of such inhibition requires further study in vivo.

Key words: D-004, free fatty acids, prostate hyperplasia, prostate 5α-reductase inhibitors

Full Text

The Full Text of this article is available as a PDF (531.2 KB).

References

  • 1.Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol. 2000;38:2–19. doi: 10.1159/000020246. [DOI] [PubMed] [Google Scholar]
  • 2.Simpson R.J. Benign prostatic hyperplasia. Br J Gen Pract. 1997;47:235–240. [PMC free article] [PubMed] [Google Scholar]
  • 3.Barry M.J., Roehrborn C.G. Benign prostatic hyperplasia [published correction appears in BMJ. 2002;324:775] BMJ. 2001;323:1042–1046. doi: 10.1136/bmj.323.7320.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Thorpe A., Neal D. Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496] Lancet. 2003;361:1359–1367. doi: 10.1016/S0140-6736(03)13073-5. [DOI] [PubMed] [Google Scholar]
  • 5.Bhargava S., Canda A.E., Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 2004;14:1–6. doi: 10.1097/00042307-200401000-00001. [DOI] [PubMed] [Google Scholar]
  • 6.Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the concept of 5alphareductase inhibition in human benign prostatic hyperplasia. Eur Urol. 2000;37:367–380. doi: 10.1159/000020181. [DOI] [PubMed] [Google Scholar]
  • 7.Carson C., III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(Suppl 1):2–7. doi: 10.1016/s0090-4295(03)00045-1. [DOI] [PubMed] [Google Scholar]
  • 8.Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the role of 5 alphareductase inhibitors in benign prostatic hyperplasia. Urologe A. 2002;41:412–424. doi: 10.1007/s00120-002-0230-2. [DOI] [PubMed] [Google Scholar]
  • 9.Michel M.C., Taguchi K., Schafers R.S. α1-Adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol. 1998;42:394–398. doi: 10.1016/s1054-3589(08)60772-3. [DOI] [PubMed] [Google Scholar]
  • 10.Sandhu J.S., Te A.E. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep. 2004;5:274–279. doi: 10.1007/s11934-004-0050-6. [DOI] [PubMed] [Google Scholar]
  • 11.Lam J.S., Romas N.A., Lowe F.C. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia. 10-Year follow-up. Urology. 2003;61:354–358. doi: 10.1016/s0090-4295(02)02149-0. [DOI] [PubMed] [Google Scholar]
  • 12.Oelke M., Hofner K., Berges R.R., Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results. Urologe A. 2002;41:425–441. doi: 10.1007/s00120-002-0236-9. [DOI] [PubMed] [Google Scholar]
  • 13.Lowe F.C., Dreikorn K., Borkowski A. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998;37:187–193. doi: 10.1002/(sici)1097-0045(19981101)37:3<187::aid-pros8>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  • 14.Plosker G.L., Brogden R.N. Serenoa repens (permixon). A review of its pharmacology and therapeutic efficacy in benign prostate hyperplasia. Drugs Aging. 1996;9:379–395. doi: 10.2165/00002512-199609050-00008. [DOI] [PubMed] [Google Scholar]
  • 15.Wilt T., Ishani A., Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(5):CD001423. doi: 10.1002/14651858.CD001423. [DOI] [PubMed] [Google Scholar]
  • 16.Carraro J.C., Raynaud J.P., Koch G. Comparison of phytotherapy (permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate. 1996;29:231–240. doi: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 17.Aliaev I.G., Vinarov A.Z., Lokshin K.L., Spivak L.G. Five-year experience in treating with prostatic hyperplasia patients with permixon (Serenoa repens Pierre Fabre Medicament) Urologia. 2002;1:23–25. [PubMed] [Google Scholar]
  • 18.Debruyne F., Koch G., Boyle P., Groupe d'etude PERMAL Comparison of a phytotherapeutic agent (permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: 1-Year randomized international study. Prog Urol. 2002;2:384–392. [PubMed] [Google Scholar]
  • 19.Willetts K.E., Clements M.S., Champion S. Serenoa repens extract for benign prostate hyperplasia: A randomized controlled trial. BJU Int. 2003;92:267–270. doi: 10.1046/j.1464-410x.2003.04316.x. [DOI] [PubMed] [Google Scholar]
  • 20.Bent S., Kane C., Shinohara K. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354:557–566. doi: 10.1056/NEJMoa053085. [DOI] [PubMed] [Google Scholar]
  • 21.Sultan C., Terraza A., Deviller C. Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochern. 1984;20:515–519. doi: 10.1016/0022-4731(84)90264-4. [DOI] [PubMed] [Google Scholar]
  • 22.Weisser H., Tunn S., Behnke B., Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5alpha-reductase activity in human prostatic hyperplasia. Prostate. 1996;28:300–306. doi: 10.1002/(SICI)1097-0045(199605)28:5<300::AID-PROS5>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 23.Iehlé C.V., Délos S., Guirou O. Human prostatic steroid 5 alpha-reductase isoforms—a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995;54:273–279. doi: 10.1016/0960-0760(95)00134-l. [DOI] [PubMed] [Google Scholar]
  • 24.Bayne C.W., Donnelly F., Ross M., Habib F.K. Serenoa repens (permixon): A 5alpha-reductase types I and II inhibitor—new evidence in a coculture model of BPH. Prostate. 1999;40:232–241. doi: 10.1002/(sici)1097-0045(19990901)40:4<232::aid-pros4>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  • 25.Habib F.K., Ross M., Ho C.K. Serenoa repens (permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005;114:190–194. doi: 10.1002/ijc.20701. [DOI] [PubMed] [Google Scholar]
  • 26.Raynaud J.P., Cousse H., Martin P.M. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of permixon. J Steroid Biochem Mol Biol. 2002;82:233–239. doi: 10.1016/s0960-0760(02)00187-5. [DOI] [PubMed] [Google Scholar]
  • 27.Rhodes L., Primka R.L., Berman C. Comparison of finasteride (proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993;20:43–51. doi: 10.1002/pros.2990220107. [DOI] [PubMed] [Google Scholar]
  • 28.Arruzazabala M.L., Carbajal D., Mas R. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exp Clin Res. 2004;30:227–233. [PubMed] [Google Scholar]
  • 29.Carbajal D., Arruzazabala M.L., Mas R. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp. 2004;65:505–514. doi: 10.1016/j.curtheres.2005.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Noa M., Arruzazabala M.L., Carbajal D. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React. 2005;27:203–211. [PubMed] [Google Scholar]
  • 31.Carbajal D., Molina V., Mas R., Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 2005;31:193–197. [PubMed] [Google Scholar]
  • 32.George F.W., Russell D.W., Wilson J.D. Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci U S A. 1991;88:8044–8047. doi: 10.1073/pnas.88.18.8044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kitahara S., Higashi Y., Takeuchi S., Oshima H. Relationship of changing steroid 5α-reductase activity to iododeoxyuridine uptake during regeneration of involuted prostates. Biol Rep. 1989;40:793–799. doi: 10.1095/biolreprod40.4.793. [DOI] [PubMed] [Google Scholar]
  • 34.Marxwell M.A., Haas S.M., Beiber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane lipoprotein samples. Anal Biochem. 1987;87:206–209. doi: 10.1016/0003-2697(78)90586-9. [DOI] [PubMed] [Google Scholar]
  • 35.Russell D.W., Wilson J.D. Steroid 5-alpha reductase: Two genes/two enzymes. Annu Rev Biochem. 1994;63:25–61. doi: 10.1146/annurev.bi.63.070194.000325. [DOI] [PubMed] [Google Scholar]
  • 36.Bombardelli E., Morazzoni P., Small J.K. Serenoa repens (bartram) Fitoterapia. 1997;68:99–113. [Google Scholar]
  • 37.Vol. 28. Pharmacopeial Convention; Rockville, Md: 2005. Saw palmetto extract; p. 425. (Expert Committee. United States pharmacopeial forum: (DSB) dietary supplement: Botanicals). No. 2. Publication USP28-NF23. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES